跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

Y0000719

紫杉醇

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价
所有图片(1)
别名:
Paclitaxel
经验公式（希尔记法）:
C47H51NO14
CAS号:
33069-62-4
分子量:
853.91
Beilstein:
1420457
MDL编号:
MFCD00869953
UNSPSC代码:
41116107
PubChem化学物质编号:
329831113
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

paclitaxel

制造商/商品名称

EDQM

mp

213 °C (dec.) (lit.)

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES字符串

[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c5ccccc5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7

InChI

1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1

InChI key

RCINICONZNJXQF-MZXODVADSA-N

基因信息

human ... TUBA1A(7846) , TUBA1B(10376) , TUBA1C(84790) , TUBA3C(7278) , TUBA3E(112714) , TUBA4A(7277) , TUBB(203068) , TUBB1(81027) , TUBB2A(7280) , TUBB2B(347733) , TUBB3(10381) , TUBB4A(10382) , TUBB4B(10383) , TUBB6(84617) , TUBB8(347688)

正在寻找类似产品? 访问 产品对比指南

相关类别

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Paclitaxel semi-synthetic for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

紫杉醇是一种有效的抗肿瘤和抗有丝分裂的紫杉烷类药物，可与 β-微管蛋白的N端结合，并使微管稳定，使细胞周期停滞在G2/M期。微管损伤通过依赖 JNK 的途径诱导细胞凋亡，随后通过不依赖 JNK 的途径诱导细胞凋亡，这可能与蛋白激酶 A（PKA）或 Raf-1 激酶的激活，进而导致 Bcl-2 磷酸化有关。通过 CYP2CB 的主要代谢物是 6α-羟基紫杉醇（6α-OHP）。

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

注意

紫杉醇可在甲醇中进行酯交换反应，并在水溶液中发生水解。

其他说明

Sales restrictions may apply.

相关产品

产品编号
说明
价格

1720000

呫吨-9-羧酸, United States Pharmacopeia (USP) Reference Standard

Y0000698

紫杉醇, European Pharmacopoeia (EP) Reference Standard

Y0000739

紫杉醇, European Pharmacopoeia (EP) Reference Standard

Y0000699

Paclitaxel impurity C, European Pharmacopoeia (EP) Reference Standard

Y0000700

峰鉴别用天然紫杉醇, European Pharmacopoeia (EP) Reference Standard

1491332

紫杉醇, United States Pharmacopeia (USP) Reference Standard

1491354

Paclitaxel Related Compound B, United States Pharmacopeia (USP) Reference Standard

1491343

头孢甘氨酸, United States Pharmacopeia (USP) Reference Standard

1491365

紫杉醇杂质混合物, United States Pharmacopeia (USP) Reference Standard

PHR1803

紫杉醇, Pharmaceutical Secondary Standard; Certified Reference Material

01517

N-Cinnamoyl-N-debenzoylpaclitaxel, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

95185

N-Debenzoyl-N-(phenylacetyl)paclitaxel, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

29914

10-O-Deacetylpaclitaxel, reference material

PHR2112

紫杉醇相关化合物B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR9146

7-O-Acetylpaclitaxel, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR9149

7-epi-Paclitaxel, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR9150

Paclitaxel impurity K, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR2111

头孢甘氨酸, Pharmaceutical Secondary Standard; Certified Reference Material

PHR3007

10-脱乙酰基巴卡汀III, pharmaceutical secondary standard, certified reference material

PHR3261

呫吨-9-羧酸, pharmaceutical secondary standard, certified reference material

象形图

Health hazard
GHS08

警示用语：

Danger

危险声明

H341,H360FD,H372

危险分类

Muta. 2 - Repr. 1B - STOT RE 1

靶器官

Central nervous system,Bone marrow,Cardio-vascular system

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

M Onrubia et al.
Current medicinal chemistry, 20(7), 880-891 (2012-12-06)
Taxol (paclitaxel) and its derivatives are microtubule-stabilizing drugs widely used in the treatment of several types of cancer, including mammary, prostate, ovarian and non-small-cell lung carcinoma, as well as AIDS-associated Kaposi's sarcoma and other types of tumor. Taxanes stabilize microtubules
Yoo-Joung Ko et al.
The Lancet. Oncology, 14(8), 769-776 (2013-05-28)
No standard treatment exists for patients with platinum-refractory urothelial cancer. Taxanes and vinflunine are commonly used, but response is less than 20% with no survival benefit. In this phase 2 study, we assessed efficacy and tolerability of nanoparticle albumin-bound (nab)
Stěpán Koudelka et al.
Journal of controlled release : official journal of the Controlled Release Society, 163(3), 322-334 (2012-09-20)
Over the past three decades, taxanes represent one of the most important new classes of drugs approved in oncology. Paclitaxel (PTX), the prototype of this class, is an anti-cancer drug approved for the treatment of breast and ovarian cancer. However
Denise A Yardley
Journal of controlled release : official journal of the Controlled Release Society, 170(3), 365-372 (2013-06-19)
Taxanes are a key chemotherapy component for several malignancies, including metastatic breast cancer (MBC), ovarian cancer, and advanced non-small cell lung cancer (NSCLC). Despite the clinical benefit achieved with solvent-based (sb) taxanes, these agents can be associated with significant and
Andrea Vecchione et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(24), 9845-9850 (2013-05-24)
Epithelial ovarian cancer is the most lethal gynecologic malignancy; it is highly aggressive and causes almost 125,000 deaths yearly. Despite advances in detection and cytotoxic therapies, a low percentage of patients with advanced stage disease survive 5 y after the
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门